drugset / Trial / NCT00183261

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

NCT00183261 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.

Timeline

Start
2006-03
Primary completion
2007-08
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MRKAd5 HIV-1 gag/pol/nef Vaccine 1 ml Intramuscular
Subject MRKAd5 HIV-1 gag/pol/nef Vaccine 1.5e+10 vg Intramuscular